Ontology highlight
ABSTRACT: Background
Gemcitabine is proven to be the first-line standard treatment of breast cancers. Yet, little is known involving gemcitabine resistance and remains largely to be elucidated.Materials and methods
We evaluated the expression of Cx43 in gemcitabine-resistant cells and parental cells by quantitative reverse transcription polymerase chain reaction (qRT-PCR) and Western blot analyses. Dual-luciferase reporter assay was applied to examine the epigenetic regulator of Cx43. The role of miR-218-5p-Cx43 axis on cell cytotoxicity, cell proliferation, colony formation, chemoresistance and migration was detected via mammalian expression vector and small short RNA (shRNA) transfection in vitro.Results
In this study, we found that Cx43 expression levels were significantly
SUBMITTER: Xia C
PROVIDER: S-EPMC6790128 | biostudies-literature | 2019
REPOSITORIES: biostudies-literature